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Abstract
More than 30% of patients with squamous cell carcinoma (SCC) of the mobile tongue have clinically unde-
tectable lymph node metastasis. Tumour cells can spread as single cells or collectively. A protein known to
play a role in both processes is podoplanin, which is expressed in endothelial cells not only in lymph vessels
but also in some aggressive tumours with high invasive and metastatic potential. Here we studied samples
from 129 patients with primary SCC of the tongue for expression of podoplanin using immunohistochemistry.
mRNA levels were analysed in another 27 cases of tongue SCC with adjacent clinically tumour-free tongue
tissue and 14 tongue samples from healthy donors. Higher levels of podoplanin were seen in tumours com-
pared to both normal tongue and clinically normal tongue in the tumour vicinity. No association was found
between levels of podoplanin, presence of lymph node metastases or other clinical factors. Patients aged 40
or less were more likely to express high levels of podoplanin protein compared to older patients (p50.027).
We conclude that levels of podoplanin in primary tongue SCCs are not associated with lymph node metasta-
ses. However, tongue SCCs arising in young patients (40 years of age) are more likely to express high levels
of podoplanin than tongue SCCs that arise in the more elderly. The data suggest that podoplanin has a dis-
tinctive role in young patients, who are known to have a poor prognosis: these patients may, therefore, bene-
fit from podoplanin inhibitory therapies.
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Introduction
The majority of intraoral squamous cell carcinomas
(SCC) are located in the mobile tongue. Compared to
tumours in other sites of the oral cavity, tongue
SCCs more frequently metastasise to cervical lymph
nodes and more than 30% of patients with tongue
SCC have occult lymph node metastasis at the time
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of diagnosis, as confirmed by histology even if clini-
cally undetectable [1]. The high frequency of spread
to lymph nodes is due to the dense lymphatic net-
work present in the tongue, with most of the lymph
fluid draining to lymph nodes in the submental and
submandibular triangles (level I) and the upper jugu-
lar nodal group (level II). This rich lymphatic net-
work also has connections across the midline,
explaining why nodal metastasis can occur on both
sides of the neck when the tumour is located in the
midline of the tongue [1]. The frequent spread to
lymph nodes from the tongue emphasises the impor-
tance of early detection for successful treatment of
tongue SCC.
Tumour cells can invade either as single cells or
collectively. Epithelial-to-mesenchymal transition
(EMT) is important in single cell invasion. During
EMT, epithelial cells lose epithelial markers such as
E-cadherin and instead acquire mesenchymal charac-
teristics including a migratory phenotype [2]. The
EMT process is regulated at the transcriptional, trans-
lational and post-translational levels [3]. The molecu-
lar and pathophysiological aspects of collective
invasion are less well understood. A protein known
to play a role in both EMT and collective invasion is
podoplanin [4].
Podoplanin is a transmembrane glycoprotein
involved in formation of lymph vessels [5]. Apart
from being expressed in endothelial cells in lymph
vessels, podoplanin can be found in, for example,
osteocytes and basal keratinocytes [5] and also in
some tumours with high invasive and metastatic
potential, including squamous cell carcinomas of the
head and neck (SCCHNs) [5]. SCCHNs with high
levels of podoplanin were reported to show signifi-
cantly higher rates of lymph node metastasis, irre-
spective of the number of lymph vessels [6]. This
finding is of clinical relevance, as diagnostic biopsies
are often of limited size and accordingly the number
of lymph vessels can be hard to estimate, whereas
expression of podoplanin in tumour cells can be eas-
ily calculated. Restriction of podoplanin expression
to the periphery of tumour nests in SCCHN has also
been shown to be an indicator of good prognosis [7].
Specifically, looking at tongue SCC, the majority of
tumours studied so far show high expression of podo-
planin. High podoplanin expression has also been
seen in the basal layer of hyperplastic and dysplastic
lesions adjacent to SCCHN and interpreted as over-
expression occurring early in head and neck tumouri-
genesis [6].
Here, we studied the prognostic impact of podopla-
nin in a large group of 129 tongue SCCs. We also
measured the number of lymph vessels in the biop-
sies to clarify their impact on the clinical course of
this disease.
Material and methods
Material
Formalin fixed, paraffin-embedded biopsies from 129
patients with primary SCC of the tongue available at
Umea˚ University Hospital and Naples, were included.
Sixty-five were men and 64 women. The mean age
was 63.4 years, ranging from 19 to 93 years. The
project was approved by the local Ethical Committee
(dnr 01-057, 03-201).
The majority of patient samples had previously
been analysed for expression of p16 and HPV16 [8].
Follow up ranged between 1 and 179 months, with a
mean of 46.6 months. All but seven patients had a
follow up of 2 years or longer.
Status at the end of the study was staged as alive
disease free, alive with disease, dead of disease, dead
disease free or dead with disease, but not as first
cause of death. Data on status were collected from
the clinical files or, when not available there, from
the Swedish Death Registry. For clinical data, see
Table 1.
Table 1. Results from scoring of podoplanin expression and number of lymph vessels in relation to age of the patient, N-status and
status at the end of the study
Podoplanin
Age group N-status Lymph vessels Status
40 41–65 >65 N0 N1 0 1–2 3 ADF DDF AWD DOD DWD
QS50 2 (11%) 2 (4%) 4 (6%) 6 (6%) 2 (6%) 5 3 0 4 4
QS51–5 2 (11%) 19 (40%) 34 (53%) 41 (43%) 14 (42%) 0 38 17 32 23
QS56–18 14 (78%) 26 (56%) 26 (41%) 49 (51%) 17 (52%) 0 56 10 32 34
129 18 47 64 96 33 5 97 27 68 61
QS5QuickScore (see text), ADF5 alive disease free, DDF5 dead disease free, AWD5 alive with disease, DOD5 dead of disease and DWD5 dead with disease,
but not as first cause of death.
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Immunohistochemistry and scoring
An antibody detecting podoplanin (D2-40; Abcam,
Cambridge, UK) was diluted 1:25. Slides were pre-
treated in TRIS-EDTA pH 8.0, and staining was per-
formed in a Ventana staining machine according to
the supplier’s recommendations. The percentage of
tumour cells expressing podoplanin as well as the
intensity of staining was assessed. The percentage of
tumour cells expressing podoplanin was divided into
six groups, where 0–4%5 1, 5–19%5 2, 20–
39%5 3, 40–59%5 4, 60–79%5 5 and 80–
100%5 6. Staining intensity in turn was described as
negative5 0, weak5 1, intermediate5 2 or strong-
5 3. By multiplying the score for percentage of
podoplanin-expressing tumour cells with the score for
staining intensity, a quick score (QS) was calculated
for each slide [9]. Scoring of slides was performed
independently by three of the authors (NS, ELJ and
KN) and cases of disagreement were reevaluated and
discussed to provide a consensus score.
The number of lymph vessels in each sample was
scored between 0 and 3, with 0 being no lymph ves-
sels detectable, 15 few, 25moderate numbers and
35many lymph vessels detectable, respectively.
qRT/PCR
Twenty-seven tongue SCCs, of which 23 had paired
clinically normal tumour-adjacent tissue samples and
14 tongue biopsies from healthy controls were
included in the mRNA analysis. For example, in the
case of a SCC on the left border of the tongue, clini-
cally normal tumour-adjacent tissue was taken from
the right side of the tongue. For clinical data on the
tumours, see Table 2. Paraffin-embedded samples
from 10 of these tongue SCC were included in the
protein analysis. Samples previously analysed [10]
had been homogenized in trizol and total RNA was
extracted using either chloroform or an RNA/protein
purification kit (Norgen). The remaining samples
were homogenized in lysis buffer from All Prep
DNA/RNA/miRNA Universal Kit (Qiagen) using
Precellys (Bertin technologies). After dilution in
water, no difference in RNA quality or yield was
observed between the different methods according to
measurement with nano-drop and bioanalyzer. For
cDNA synthesis, 500 ng of total RNA was used with
RevertAid H minus first strand cDNA synthesis kit
(Thermo Scientific). cDNA was diluted 53 and 2.5
ml used in each reaction with a total reaction volume
of 10 ml. For PCR amplification of cDNA, IQ sybr
green supermix (Bio-Rad) was used in combination
with primers for podoplanin (Bio-Rad assay ID
qHSaCID 0009013) and reference primers: GAPDH,
UBC, LAD1, RPS12 from PrimerDesign Ltd. For
GAPDH and UBC the company does not give out
sequences. LAD1 (For: CCTCCCACCCGTCACACT,
Rev: CTGCTGTAGGTTCGCTGTGT), RPS12 (For:
TGCTGCTGGAGGTGTAATGG, Rev:GCACACAA
AGATGGGCTTGG.
Cycling conditions: enzyme activation at 958C for
3 min, denaturation at 958C for 15 s and annealing at
608C for 60 s. The process was run for 40 cycles.
To normalize the values, a geometric mean from
the reference genes GAPDH, UBC, RPS12 and
LAD1 was used in the calculation of 22DCq.
Statistical analysis
SPSS version 22 was used for statistical analysis,
correlating results from scoring of podoplanin to clin-
ical data. The Chi square test was used for calcula-
tion of p-values and a p-value <0.05 was considered
statistically significant. Two- and 5-year survival
were used in the survival analysis. Mann-Whitney
test was used to analyse mRNA levels.
Table 2. Clinical data on 27 tumours included in the analysis of
podoplanin mRNA
Nr Sex Age Localisation TNM
20 Male 61 1 T1N0M0
35* Female 24 2 T2N0M0
40 Female 81 3 T4N2bM0
49* Female 52 3 T4N2cM0
51* Male 74 1 T2N0M0
56 Female 41 3 T2N2bM0
58* Male 61 1 T1N0M0
59* Female 68 1 T2N0M0
61 Male 70 3 T4aN0M0
65* Female 81 3 T2N0M0
68 Male 62 1 T2N0M0
70* Male 71 2 T1N0M0
73 Male 81 3 T4aN0M0
76 Male 59 3 T4aN0M0
79 Male 61 2 T1N0M0
82* Female 19 1 T4N0M0
83* Female 64 2 T1N0M0
85* Female 87 1 T2N0M0
92 Female 63 2 T2N0M0
98 Male 31 3 T2N0M0
105 Male 64 2 T1N0M0
111 Female 31 2 T1N0M0
119 Male 66 2 T2N0M0
124 Male 54 3 T4N2bM0
131 Female 74 2 T2N0M0
137 Female 71 2 T2N0M0
138 Male 50 1 T2N1M0
For tumour localisation 15 tongue, 25 border of tongue and 35 over-
growth into floor of mouth.
Tumours labelled with * also had paraffin samples included in the protein
analysis. TNM5 T(umour), N(odes), M(etastasis).
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Results
Clinical data
At 2-year follow up, which was available for 122 of
the 129 patients studied, 75 were alive and 47 dead.
Considering age, 56% of patients 40 years were alive
2 years after diagnosis, in contrast to 73% of patients
aged 41–65, but similar to 54% of patients >65 years.
At 5 years (follow up available for 101 patients of
whom 48% were alive), 39% of patients 40 years
were alive, in contrast to 65% of those aged 41–65
years but similar to 37% of patients >65 (p5 0.009).
For status at the end of the study, see Table 1.
Expression of podoplanin
Of the 129 tongue SCC samples, 8 (6%) were nega-
tive for podoplanin, 55 (43%) showed low expression
(QS 1–5) and 66 (51%) showed high expression (QS
6–18) (Figure 1). A significantly higher percentage
of tumours in patients aged 40 years (78%) showed
high expression of podoplanin (QS5 6–18), com-
pared to 56% and 41% of the 41–65 and >65-year-
old patients, respectively (p5 0.027) (Table 1).
Looking at the whole group of patients, there was no
significant association between expression of podopla-
nin (QS), N-status, T-status, gender or localisation.
Lymph vessels were detectable in all but five sam-
ples, with 52% showing a moderate number. The five
samples lacking detectable lymph vessels were also
negative for podoplanin in the tumour tissue. Of the
94 samples with a lymph vessel score of 2 or 3, all
but two expressed podoplanin. No significant associa-
tion was seen between the presence of lymph vessels,
age, gender, T- or N-stage or status at the end of the
study (Table 1).
Levels of podoplanin mRNA
All 27 tumours analysed showed significantly higher
levels of podoplanin mRNA compared to both
healthy controls, and clinically normal tongue tissue
adjacent to the tumours (p< 0.0001). In the group of
tumour-adjacent tongue tissue, levels were also sig-
nificantly higher compared to healthy normal tongue
(p5 0.005). Inter-individual variation in podoplanin
levels was seen in tumours, with the highest levels
seen in two females, one 24 years old (no 35) and
the other 41 years old (no 56) (Figure 2).
Figure 1. (A–C) Representative podoplanin immunohistochemistry in tongue SCC with different QuickScores (QS), as indicated. (D)
Podoplanin-expressing tumour cells showing perineural growth.
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Discussion
Tongue SCC is a severe disease, which shows an
increase worldwide, especially among young people
and particularly women [11]. The disease may have
an unpredictable outcome and the known worse prog-
nosis for young patients [8,12] was also clearly seen
in the present material, where only 39% of patients
40 years were alive after 5 years compared to 65%
of those aged 41–65 years.
One of the biggest challenges with tongue SCC is
that 30% of clinically node negative tumours have
occult lymph node metastasis at diagnosis [1]. How-
ever, without performing a staging neck dissection it is
not possible to pinpoint these 30%. The tongue, with
its well-developed lymphatic network, is ideal for easy
spread of tumour cells and, as N-status is a factor of
known prognostic significance, it would be valuable to
identify at the time of diagnosis factors that can aid in,
or precede development of, nodal spread.
A factor of potential importance in this aspect is the
lymph vessel-specific glycoprotein podoplanin. Previ-
ous results concerning its role in tumour spread are
contradictory, where some claim that it induces EMT
[13] whereas others instead show that it forms filopo-
dia and in that way induces collective cell migration
[14].
Podoplanin expression has been reported in mucosa
adjacent to SCC [15] and this has been interpreted to
indicate that the protein is expressed early in the
tumourigenic process [16]. Our results from mRNA
analysis support this interpretation as levels of podo-
planin in clinically normal tongue adjacent to tumour
were significantly higher than those in normal tongue
taken from healthy volunteers with no evidence of
SCC or other disease. Levels in tongue SCC were
also significantly higher compared to both groups. At
the protein level, there was no tendency for lowered
expression in later stages of the tumourigenic pro-
cess. On the contrary, 61% of N1 tumours showed
high podoplanin expression, judged as QS 6–18,
compared to 51% of N0 tumours. Although the num-
ber of cases are low, none of the eight podoplanin
negative tumours was T4, whereas seven of them
were T1 and T2.
Our figures for podoplanin expression with 6%
negative, 43% low expressing (QS 1–5) and 51%
high expressing (QS 6–18) tumours are comparable
to the findings of Yuan and coworkers [6]. In con-
trast to their findings and also to another study [16],
we found no association between high expression of
podoplanin and lymph node metastasis or prediction
of poorer outcome. In Yuan’s material, 89% of the
28 N1 tongue SCC showed high levels of podopla-
nin, compared to 52% of our 33 N1 tumours. As the
scales for evaluating percentage of podoplanin-
expressing tumour cells differ between the two stud-
ies, it is not possible to fully compare these results.
Bartuli et al [17] analysed a mixed group of 20 SCC,
of which only 12 were located in the tongue com-
pared to our group of 129 tongue SCCs. A limited
group of 12 tumours may thus not be representative
of the whole group of tongue SCCs.
As has been seen previously, patients 40 years
are a specific group and, in this study, showed the
significantly highest percentage of high podoplanin-
expressing tongue tumours. Even if there was no dif-
ference in outcome for these young patients with
Figure 2. Top: Mean levels of podoplanin mRNA in 27 tongue
SCCs (T), 23 matched clinically normal tongue samples adjacent
to tumour (N) and 14 tongue samples from healthy controls (C).
****p< 0.0001, **p5 0.005. The levels of podoplanin mRNA in
individual patients, matched clinically normal tongue adjacent
to tumour and normal tongue from healthy controls are shown
in the lower panel.
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high podoplanin expression, it is noteworthy that this
group, once again, differs from the majority of
patients with tongue SCC, who are typically much
older.
Concerning the number of lymph vessels, no associa-
tion with any clinical factor was seen. It must, however,
be emphasized that the calculation of lymph vessel
number in diagnostic biopsy material is not optimal and
not representative of all aspects of the whole tumour.
Thus, the potential relevance of lymph vessel numbers
cannot be excluded based on the present results.
In summary, we have measured podoplanin levels at
both protein and mRNA level in tongue SCC and found
significantly higher levels in tumours compared to nor-
mal tongue as well as to clinically normal tongue in the
tumour vicinity. In contrast to other studies, we could
not confirm the correlation seen between podoplanin
levels and the presence or absence of lymph node
metastases. However, we show that tongue SCC arising
in patients 40 years of age has the significantly high-
est percentage of high podoplanin expressing tumours.
The clinical value of this finding remains to be deter-
mined but suggests that targeting podoplanin with anti-
bodies or lectins [18] could be particularly useful for
the group of young patients with tongue SCC.
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